Tuesday December 23, 2014 0 comments
BOULDER - N30 Pharmaceuticals Inc., a clinical-stage, biopharmaceutical company focused on development of therapies for cystic fibrosis, announced its board of directors has appointed Jon Congleton to be the firm's president and CEO.
Congleton will also join N30's board of directors.
Congleton, who previously served for 18 years at Teva Pharmaceuticals Ltd. in a variety of upper management roles, brings more than 25 years of senior management and product commercialization experience in the pharma industry to N30.
"It is an exciting time to be joining N30 Pharmaceuticals, with the company's lead compound --- N91115 for cystic fibrosis - moving through Phase 1 clinical trials after encouraging early data," Congleton said.
"N91115 is intended to address a significant unmet need in the treatment of cystic fibrosis, and I look forward to working with the N30 team to advance this novel compound through clinical development."
N30 Pharma recently secured $30 million in a private placement of its preferred stock, with proceeds targeted to advance the company's N91115 clinical trial program.
"Jon's mix of business development, operations and commercialization experience make him well-suited to drive N30 through its next phase of development," said Howard Furst, N30 board chair and partner at Deerfield Management Company LP.
"Jon is an industry veteran with an excellent reputation for growing organizations, driving corporate development activities and building and commercializing (product) pipelines and we believe the company will build upon its solid foundation under his leadership."